- 1 Title page
- 2 Immunogenicity and Safety of a 14-valent pneumococcal polysaccharide conjugate vaccine
- 3 (PNEUBEVAX 14TM) administered to 6-8 weeks old healthy Indian Infants: A single blind,
- 4 randomized, active-controlled, Phase-III study
- 5 Ramesh V Matur¹, Subhash Thuluva¹, Subbareddy Gunneri¹, Vijay Yerroju¹, Rammohan reddy
- 6 Mogulla¹, Kamal Thammireddy¹, Piyush Paliwal¹, Niranjana S Mahantshetty², Mandyam Dhati
- 7 Ravi³, S. Prashanth⁴, Savita Verma⁵, Jai Prakash Narayan⁶.
- 8 **Affiliations:** ¹Biological E Limited, 18/1&3, Azamabad, Hyderabad 500 020, Telangana,
- 9 India; ²KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Department of
- 10 Pediatrics, Belgaum, Karnataka, India.; ³JSS Hospital, Department of Pediatrics, Mysore,
- 11 Karnataka India; ⁴Cheluvamba Hospital, Mysore Medical College & Research Institute, Dept. of
- Paediatrics, Mysore, Karnataka, India; ⁵Pandit Bhagwat Dayal Sharma Post Graduate Institute of
- Medical Sciences & Hospital, Department of Pharmacology, Rothak, Haryana, India; ⁶Jawahar
- Lal Nehru Medical College, Kala Bagh, Rajasthan, India.
- 15 Corresponding Author Name: Ramesh V Matur, Biological E Limited, 18/1&3, Azamabad,
- 16 Hyderabad 500 020, Telangana, India,
- 17 **E-mail:** Ramesh.Matur@biologicale.com
- 19 **Funding Support**: The study was funded by Biological E Limited, 18/1&3, Azamabad,
- 20 Hyderabad 500020, Telangana, India

ABSTRACT

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

Background: Introduction of pneumococcal conjugate vaccines (PCV) reduced the cases of pneumococcal disease at global level. However, there is an increase in clinical and economic burden of PD from non-PCV serotypes, particularly in pediatric and elder population. In this study, immunogenicity and safety of the BE's 14-valent PCV (PNEUBEVAX 14TM; BE-PCV-14) containing two additional epidemiologically important serotypes (22F and 33F) in comparison to PCV-13 was evaluated in infants. **Methods:** This is a pivotal phase-3 single blind randomized active-controlled study conducted at 12 sites across India in 6-8 weeks old healthy infants in 6-10-14 weeks dosing schedule to assess immunogenic non-inferiority and safety of a candidate BE-PCV-14. In total, 1290 infants were equally randomized to receive either BE-PCV-14 or PCV-13. Solicited local reactions and systemic events, adverse events (AEs), serious AEs (SAEs) and medically attended AEs (MAAEs) were recorded. Immunogenicity was assessed by measuring anti-PnCPS IgG concentration and functional antibody titers by opsonophagocytic activity (OPA), one month after completing three dose schedule. Cross protection to serotype 6A offered by serotype 6B was also assessed in this study. **Findings:** The safety profile of BE-PCV-14 was comparable to PCV-13 vaccine. Majority of reported AEs were mild in nature and no severe or serious AEs were reported. Primary immunogenicity objective was met for all 14 serotypes. For the twelve common serotypes non-inferiority to those 12 serotypes in PCV-13 was met. Additional serotypes in BE-PCV-14 (22F and 33F) also met NI criteria as defined by WHO TRS-977. A significant seroconversion, about 69% for serotype 6A was observed even though this antigen was not present in BE-PCV-14. This indicates that

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

serotype 6B of BE-PCV-14 cross protects serotype 6A. BE-PCV-14 also elicited comparable serotype specific functional OPA immune responses to all the serotypes in PCV-13. **Interpretations:** BE-PCV-14 was found to be safe and induced robust and functional serotype specific immune responses to all 14 serotypes. All serotype-specific IgG responses were comparable to those in PCV-13. These findings suggest that BE-PCV-14 can be safely administered to infants and achieve protection against pneumococcal disease caused by serotypes covered in the vaccine. study was prospectively registered with clinical trial registry India-CTRI/2020/02/023129 **KEY WORDS:** Infants, Pneumococcal disease, Conjugate vaccine, Serotype, Pneumococcal capsular polysaccharide, Opsonophagocytic activity.

INTRODUCTION

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

Streptococcus pneumoniae is a gram positive bacterium, causing morbidity and mortality globally in children under 5 years, adults above 50 years and in individuals with comorbidities. It manifests a variety of invasive or noninvasive diseases such as pneumonia, otitis media, nasosinusitis, bacteremia and meningitis 1,2. Most of the deaths are caused by invasive pneumococcal disease (IPD) with reported >300000 deaths worldwide in children under 5 years every year due to pneumonia or meningitis ³. In developing countries, case fatality rates may be as high as 50% for meningitis and up to 20% for septicemia. As per a global population-based model in 2015 and as per WHO data, case fatality rates under 5 years' is the highest in India followed by Pakistan, Bangladesh, Sri Lanka and Indonesia with reported incidences over 200/100,000 population ^{4,5}. Although there are more than 95 identified serotypes of S pneumoniae, few serotypes are responsible for causing the disease ⁶. In addition, in more than 30% of cases, pneumococcal bacteria are resistant to one or more antibiotics ⁷. A 23-valent, unconjugated pneumococcal polysaccharide vaccine (PPSV23; Pneumovax® 23, Merck and Co., Inc., NJ) provides only transient protection as it elicits T-cell independent immune responses⁸. Pneumococcal polysaccharide-protein conjugate vaccines (PCVs) 7- and 13valent (PCV-7; Prevenar 7[®]; PCV-13; Prevenar 13[®]; Pfizer, New York), were able to induce Tcell dependent immune response against respective serotypes and generate robust functional antibody responses providing long-term protection against IPD across different age groups 9-11. Introduction of PCVs substantially reduced the burden of IPD worldwide in all age groups ¹². Despite these reductions, one-fourth to one-third of the S. pneumoniae serotypes causing IPD are not covered by currently available PCVs and these serotypes bring about a significant unmet medical need ¹³⁻¹⁵. A study by Balsells, et al. ¹⁶ reported that 42.2% of childhood IPD cases were

caused by non-vaccine serotypes. So, it is important to include additional serotypes to minimize the burden of IPD. Biological E Limited developed a PCV covering 14 different serotypes (PNEUBEVAX 14TM) including 2 serotypes (22F and 33F) that are not included in PCV-13. These two serotypes were reported to be among top 11 predominant non-vaccine serotypes, which accounted for 22% of invasive pneumococcal disease cases in India under-five years ^{17,18}. A recent study ¹⁹, also reported that 22F and 33F as the most prevalent non-PCV13 serotypes causing IPD ²⁰. Moreover, these two serotypes are among the first to increase in replacement disease after introduction of PCV-7 and PCV-13 vaccines ¹⁹, ²⁰. Accessibility to PCVs with additional serotypes can be increased when the vaccines are developed in a country such as India that is among countries with the major disease burden. Safety and immunogenicity of BE-PCV-14 was established in phase-1 and phase-2 studies in healthy adults and toddlers respectively (CTRI/2017/06/008759 and CTRI/2017/11/010387). Here we report the immunogenicity and safety of BE-PCV-14 in 6-8 weeks old healthy infants (n=1290) in 6-10-14 weeks dosing schedule and PCV-13 was used as a comparator to demonstrate the immunogenic non-inferiority.

METHODS

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

Study Design and Participants

The phase-3, two arm, single blind, randomized, active-controlled study was conducted between February 2020 and March 2022 in India across 12 sites. Study was designed to evaluate the immunogenic non-inferiority and safety of a BE-PCV-14 administered to 6-8 weeks old healthy infants in 6-10-14 weeks dosing schedule. Participants were equally randomized (1:1) to receive either BE-PCV-14 (test) or PCV-13 (Prevenar 13[®], comparator). In total, 1290 subjects were enrolled into the study (n=645 in BE-PCV-14 arm and n=645 in PCV-13 arm). A dose of 0.5mL

of the study vaccine (BE-PCV-14 or PCV-13) was administered intramuscularly in a three dose vaccination schedule (3+0) with a 4-weeks interval. All enrolled subjects (N=1290) were healthy infants with ≥3300 grams weight at the time of screening. None of the subjects received any licensed or investigational pneumococcal vaccine prior to enrollment. Other permitted vaccines included single dose of BCG, hepatitis B, DTwP-HepB-Hib (liquid pentavalent), polio and rotavirus vaccines. Informed consent was obtained from subjects' parent(s) prior to performing any study specific procedure. Exclusion criteria used were evidence of previous S. pneumoniae infection, use of any investigational or non-registered product (drug or vaccine) -30 days prior to study vaccine administration, history of any neurological disorders, meningitis, or seizures, family history of congenital or hereditary immunodeficiency, history of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity likely to be exacerbated by any component of the study vaccines. Complete list of eligibility criteria provided as supplementary information. The study was conducted in accordance with the principles defined in the Declaration of Helsinki, International Conference on Harmonization guidelines (Good Clinical Practices), and the new drug and clinical trial rules, 2019 ²¹. The investigational review board or ethics committee at each study site approved the protocol. **Randomization and masking:** Eligible subjects were randomized to receive either BE-PCV-14 or PCV-13 in 1:1 ratio and

randomization numbers were assigned using an interactive web-based randomization system (IWRS). Randomization sequence was generated using SAS software (SAS Institute Inc, 100 SAS Common Prime Comm NC 27513 2414 JUSA)

SAS Campus Drive, Cary, NC 27513-2414, USA).

Procedure

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

Screening, enrolment, and first dose of primary vaccination was done when infants were 6-8 weeks old (visit-1; day 0). Second and third doses of primary vaccination (visit-2; day 28 and visit-3; day 56) and a final follow up immunogenicity visit (visit-4, day 86) took place at four weeks' interval. An additional time window of +7 days for the second, third, and the fourth visit was permitted to ensure subject's visit compliance. Each 0.5mL of single human dose of BE-PCV-14 (PNEUBEVAX 14TM) contained 3µg of serotype 1 and 2.2µg of each of serotypes 3, 4, 5, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F and 4.4 µg of serotype 6B polysaccharides conjugated to about 35 µg of non-toxic diphtheria toxin cross-reacting material 197 (CRM₁₉₇) protein and adsorbed onto ≤0.75 mg of aluminium phosphate (Al+++). The 13-valent Pneumococcal polysaccharide conjugate vaccine "PCV-13" (control vaccine) contained 2.2 ug of each of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides, and 4.4µg of 6B saccharide, 34µg CRM₁₉₇ carrier protein, and 125µg aluminum as aluminum phosphate adjuvant. Both vaccines were administered in the anterolateral aspect of thigh. Approximately 5.0 mL of blood was collected at visit-1(day 0) and again at visit-4 (day 86). Anti-PnCPS IgG antibody concentration estimation against each of the 14 vaccine serotypes was performed as per the WHO reference ELISA assay 22 with a minor modification. Cell wall polysaccharide (CWPS) multi was used instead of CWPS and 22F PnPS for pre-absorption to neutralize non-specific antibodies and other common contaminants present in the PnPS coating antigens. Functional antibody responses against all 14 serotypes were assessed by opsonophagocytic activity (OPA) assay, which was performed at WHO pneumococcal serology

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

reference laboratory (UCL Great Ormond Street, Institute of Child Health, Immuno-biology Section, United Kingdom). Each vaccinated infant was observed for at least 60 minutes after vaccination to evaluate and treat for any immediate adverse reactions. At each vaccination visit, a diary card was provided to the subject's parent(s)/LAR[s] to record any solicited local/general AE occurring after vaccination for 7 consecutive days (day 0 - day 6). List of solicited local and systemic AEs are provided as supplementary information. Unsolicited AEs, serious adverse events (SAEs), medically attended adverse events (MAAEs) were recorded until the end of the study. Severity of all AEs was graded as per the common terminology criteria for adverse events (CTCAE V5.0) or division of AIDS (DAIDS) table version 2.0. Brighton collaboration scale was taken for severity grading of fever. All AEs were assessed for relatedness to study vaccine by the investigator. **Outcomes:** Primary outcome of the study was to demonstrate serotype specific immunogenic non-inferiority (NI) of BE-PCV-14 to licensed PCV-13 vaccine one month after the completion of primary vaccination series against 12 common serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in terms of number of subjects seroconverted and the ratio of IgG geometric mean concentrations (GMCs). Immunogenic NI for new serotypes 22F and 33F in BE-PCV-14 was demonstrated by comparing immunoglobulin G (IgG) concentrations induced by serotypes 22F and 33F of BE-PCV-14 with one of the PCV-13 serotypes that showed the lowest sero-response. Sero-response or seroconversion rate was defined as proportion of vaccinated infants with serotype specific IgG antibody concentrations of at least $\geq 0.35 \mu g/ml^{23}$.

One of the secondary objectives of the study was to assess the immune response in terms of serotype specific opsonophagocytic activity (OPA) in a randomly chosen subset of subjects from the BE-PCV-14 group compared with an equal number of subjects randomly chosen from PCV-13 vaccinated group. Other secondary outcome was to evaluate the safety of BE-PCV-14 in comparison with PCV-13 measured by the incidence rates of reactogenicity events (local reactions and systemic events) and adverse events (AEs).

Statistical Analyses

Sample size determination:

Sample size estimation was based on the 2-sided 95% confidence interval (CI) for the difference in proportion of subjects achieving a serotype-specific pneumococcal IgG concentration ≥0.35µg/mL in each vaccine group. After study completion, a two-sided 95% confidence interval for the true difference between the two proportions was constructed. The lower bound of the confidence interval was to lie entirely on the positive side of the -10% points margin to demonstrate non-inferiority.

Data from the phase-II safety and immunogenicity study in 12 to 23 months old children conducted in India (CTRI/2017/11/010387) was used to support sample size estimation. The power was computed for an anticipated test vaccine group proportion of 92.33% within the non-inferiority margin set. The significance level of the test was targeted at 0.025. Accordingly, sample sizes of 581 in each group was estimated to achieve 90% power and to detect a non-inferiority margin difference between the group proportions of -0.10. An anticipated, not more than 10% dropout rate was built-in to the sample size. Therefore, the overall sample size required was 645 infants per group to obtain 581 evaluable infants per group at the end of the study.

Statistical analyses

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

All demographic and baseline characteristics of both the groups were presented using intend-to treat (ITT) population, defined as all subjects randomized into the study. The data was analyzed by summary statistics. All subjects who received at least one dose of the study vaccine were included in the safety analysis and the datawas summarized descriptively. For continuous variables n, mean, standard deviation, median and range (minimum, maximum) have been presented. For categorical data, frequencies were computed. All reported adverse events during the entire study period were summarized by calculating frequencies and listed per subject including severity and relationship (causality). The number and percentage of subjects with AEs were presented by system organ class and preferred term. All medically attended AEs reported during the study were listed and analyzed for expectedness and causality. Two-sided 95% exact confidence intervals were calculated for all the occurrence rates of reported AEs and SAEs during the study. All AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRATM; version 25.1) coding dictionary and concomitant medications have been coded using the World Health Organization (WHO) Drug Dictionary, March 2022. Immunogenicity assessment was based on the per-protocol population defined as the vaccinated subjects whose blood samples were available for immunogenicity analysis at both baseline and day 86 (visit-4). Non-inferiority of serotype specific immune responses induced by BV-PCV-14 against PCV-13 was assessed by one of the below two criteria as per the WHO defined criteria²³. 1. By measuring difference in proportion of subjects seroconverted to achieve serotype specific anti-PnCPS IgG concentration $\geq 0.35~\mu g/ml$ between BE-PCV-14 and PCV-13. The lower limit of 95% CI for the difference in proportion subjects seroconverted between BE-PCV-14 and PCV-13 should be above the minus 10% points.

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

2. By assessing the IgG GMC ratio (BE-PCV-14/PCV-13) along with its two sided 95% confidence interval. Non- inferiority was considered achieved if the ratio of lower limit of two sided 95% CI (test /control group) was above the pre-specified margin of 0.5. For two new serotypes 22F and 33F which were not part of PCV-13, non-inferiority was assessed by comparing with any serotype in the PCV-13 group that achieved the lowest percentage of ≥0.35µg/ml IgG GMC. For serotype 6A, which was not in BE-PCV-14 but present in PCV-13, a \geq 2-fold increase in the 6A specific geometric mean concentrations (GMCs) above pre-vaccination levels was assessed as an exploratory outcome. Proportion of subjects achieving ≥4-fold rise in anti-PnCPS IgG antibody concentrations from baseline and geometric mean fold rise (GMFR) along with their 2-sided 95% CI against each of the vaccine serotype was calculated. As a secondary outcome, proportion of subjects achieving a serotype-specific OPA titre≥1:8 post vaccination was assessed along with 2-sided 95% confidence. Serotype specific OPA geometric mean titres (GMT) along with their ratios and GMFR against 12 common serotypes in both vaccine groups was evaluated. A reverse cumulative distribution (RCD) curve of anti-PnCPS antibody concentrations and OPA GMT titers by serotype of BE-PCV-14 and PCV-13 were plotted for all common vaccine serotypes in both groups. **RESULTS** A total of 1290 subjects were screened and randomly assigned to receive either BE-PCV-14(n=645) or PCV-13 (n=645) study vaccine. Out of 1290 subjects, 1267 (98.2%) subjects (641 in BE-PCV-14 arm and 626 in PCV-13 arm) completed all the visit specific procedures and were included in the immunogenicity (anti-PnCPS IgG antibody concentration) analysis. In total, 22

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

(1.7%) subjects were dropouts. Subject disposition with reason for dropout from the study was presented in Figure 1. Safety analyses were performed in all enrolled subjects (n=1290) whereas immunogenicity (per-protocol population) was completed in 1267 subjects. One subject was excluded from per-protocol population due to insufficient serum sample and the rest (n=22) were dropouts. Demographics of intention-to-treat population were presented in Table 1. Age of the subjects and male to female ratio was comparable in both BE-PCV-14 and PCV-13 arms. Summary of other eligible vaccinations received by study subjects was presented in Supplementary Table 1. The proportion of subjects with anti-PnCPS IgG antibody concentrations equal to or above the protective threshold ≥0.35µg/mL (primary outcome) at day 86 in BE-PCV-14 (n=641) group was in the range of 76.3% (serotype6B) to 99.7% (serotype 14) and in the PCV-13 (n=626) group, the response rate was in the range of 77% (serotype 3) to 100% (serotype14) for 12 common serotypes. The lower limit of 95% CI for the difference in proportion of subjects seroconverted between BE-PCV-14 and PCV-13 was above the minus 10% points for all the 12 common serotypes (serotype 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) and all of them met predefined NI criteria. The distributions in serotype-specific IgG concentrations for 12 common serotypes in both vaccine groups were similar, as shown by the reverse cumulative distribution curves (Figure 3). Seroresponse rates for serotype 22F (94.1%) and 33F (73.2%) that are present only in BE-PCV-14 group were compared with the lowest performing serotype 3 (77.0%) in PCV-13 group. Defined NI criteria was met for both serotypes 22F and 33F (Figure 2a). For IgG geometric mean concentrations, NI criteria was achieved for all 12 common serotypes and for additional 22F and 33F serotypes (Figure 2b). The lower bound of the 95% CI for GMC

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

ratio was in the range of 0.67 (serotype 1) to 1.10 (serotype 3) for 12 common serotypes present in BE-PCV-14 and PCV-13. For serotype 3 and serotype 14, lower bound 95% CI was 1.10 and 1.01 respectively, indicating that BE-PCV-14 induces strong immune response compared to PCV-13. Serotypes 22F and 33F, which are not present in PCV-13, the lower bound of the 95% CI for GMC ratio was 5.26 and 1.82 respectively (Figure 2b), when compared to the lowest performing serotype in PCV-13 (serotype 3). The proportion of subjects achieving a serotype-specific OPA titer ≥LLOQ (≥1:8) at day 86 were in the range of 63.64% (serotype-1) to 98.43% (serotype-22F) in BE-PCV-14 group and 64.43% (serotype-1) to 98.46% (serotype-7F and serotype-23F) in PCV-13 group. Overall, the OPA GMTs were comparable among all common serotypes in both vaccinated groups (Table 2). The additional serotypes 22F and 33F in BE-PCV-14 vaccine had 15.16 and 16.91-fold rise in OPA GMTs respectively at day 86 compared to pre-vaccination levels, signifying that both the additional serotypes can induce high levels of protective functional antibodies in vaccinated infants (Table 2). The proportion of subjects achieving ≥4-fold increase in anti-PnCPS IgG antibody concentrations at day 86 from baseline is presented in Table 3. BE-PCV-14 vaccine has serotype 6B and no serotype 6A. In this study, we tested the cross protection against serotype 6A, assessed by a ≥2-fold increase in the 6A specific IgG antibody concentrations and the OPA antibody titers above the pre-vaccination levels. There was 2.4-fold (pre-vaccination GMC: 0.45 and post-vaccination GMC: 1.08) and 7.64-fold (OPA GMT were 16.59 and 134.50 for pre- and post-vaccination, respectively) increase in serotype 6A specific IgG and OPA antibody titers respectively (Table 4). Our data on serotype 6A specific 69.7% seroconversion and 2.4-fold rise in GMC in BE-PCV-14 vaccinated infants along with functional

antibody titers (OPA) GMFR of 7.64 fold strongly suggests that the serotype 6B confers significant immunological cross protection against serotype 6A. The current study demonstrated that BE's 14-valent pneumococcal polysaccharide conjugate vaccine, administered in a 3-dose schedule (6-10-14 weeks), was safe, immunogenic and noninferior to PCV-13 for the 12 common serotypes. Among all vaccinated infants (n=1290), 175/645 (27.1%) subjects and 178/645 (27.6%) subjects reported at least one adverse event in BE-PCV-14 and PCV-13 groups respectively. All the reported adverse events were generally mild and only very few cases were moderate in their intensity. Majority of the reported adverse events were solicited in nature and related to the study vaccine. Overview of the reported AEs including solicited and unsolicited AEs were presented in Table 5. Summary of AEs by system organ class (SOC) and preferred term (PT) were shown in Table 6. No severe or serious AEs were reported in either of the vaccine groups. Overview of AEs by severity grade and causality to the study vaccine were presented in Table 7. Summary of local, solicited systemic and unsolicited AEs by SOC and PT were presented in Supplementary Table 2, 3 and 4. No clinically significant changes overtime were noted in the vital signs. The AEs observed and physical examination results did not indicate any safety issues of concern. Overall, the safety profile of BE-PCV-14 was comparable to the control vaccine PCV-13 in terms of AE rates, related AE rates and medically attended AEs and found to be safe and well tolerated.

DISCUSSION

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

In this phase-3 trial, immunogenic non-inferiority, safety, and reactogenicity of a candidate BE-PCV-14 vaccine administered to 6-8 weeks old healthy infants in 6-10-14 weeks dosing schedule was evaluated. Robust and functional immune responses were elicited by BE-PCV-14 one month

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

after the third vaccination dose. Primary basis for NI comparison and licensure decisions were based on reaching IgG concentrations ≥0.35µg/ml for all vaccine specific serotypes in the new vaccine and the licensed comparator. In accordance with WHO TRS 977 guidelines ²³, all 12 common serotypes in BE-PCV-14 met the non-inferiority criteria with those serotypes in PCV-13 in terms of both seroconversion rates (percentage of subjects with $IgG \ge 0.35 \mu g/ml$) and GMC ratios (≥0.5). Both BE-PCV-14 and PCV-13 generated comparable functional immune responses (OPA titres), similar to IgG response. In the current study, we evaluated the cross-protection offered by serotype 6B against serotype 6A in BE-PCV-14 vaccinated group. Serotype 6A and 6B have high structural similarity of polysaccharide ^{24,25}. Therefore, it was expected that the immune responses induced by serotype 6B would provide at least partial cross-protection against serotype 6A in humans. An earlier study reported that PCV-13 elicits cross-functional opsonophagocytic killing responses in humans to serotypes not directly covered by the vaccine ²⁶. In this study, cross-protection was assessed by a ≥2-fold increase in the 6A specific IgG antibody concentrations and the OPA antibody titers above the pre-vaccination levels. We found 2.4-fold and 7.64-fold increase in IgG GMC and OPA titers respectively, against serotype 6A in BE-PCV-14 vaccinated subjects, suggesting that BE-PCV-14 vaccine can offer protection against serotype 6A even though this serotype antigen is not present in BE-PCV-14. The serotype 6A cross protective functional immune response elicited by BE-PCV-14 is notably robust and strong when compared to another 10-valent PCV as described elsewhere ²⁷. This clearly indicates that serotype 6B in BE-PCV-14 affords significant cross protection to serotype 6A. Our results are consistent with previous studies, where it was shown that 23-valent polysaccharide vaccine lacking serotype 6A and carrying serotype 6B elicited cross-functional immune responses against serotype 6A ^{28,29}.

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

Vaccine effectiveness (VE) against IPD was established in pediatric population for PCV-13 specific serotypes and it was found to be around 55% 30. Breakthrough IPD was mainly caused by serotype 3 and 19A in PCV-13 vaccinated children. Excluding serotype 3 and 19A, VE of PCV-13 against rest of the vaccine serotypes was reported to be 89% 30. BE-PCV-14 was noninferior to PCV-13 for all shared serotypes and against 2 unique serotypes (22F and 33F) when compared against lowest performing serotype 3 from PCV-13. Importantly, 83.5% of BE-PCV-14 vaccinated children seroconverted against serotype 3 while 77% seroconverted to serotype 3 in PCV-13 group. Several studies worldwide have shown that substantial proportion of pneumococcal disease is caused by non-vaccine serotypes, predominantly by serotype 22F (13.4%) and 33F (21%) ^{19,31,32}. Another 15 valent PCV carrying these two serotypes was shown to induce serotype 22F and 33F immune response when compared to PCV-13 33. Similarly, the present study also demonstrates that BE-PCV-14 elicited serotype specific (22F and 33F) superior immune responses (Figure 2b). BE-PCV-14 containing 12 common serotypes and 22F and 33F serotypes along with cross protection to serotype 6A can protect the susceptible population against pneumococcal disease and may also provide herd immunity. One limitation of the current study is that it is conducted in only Indian infant population and need to conduct similar studies in other regions. However, based on the VE and post marketing experience with PCV-13 across different geographical regions, it is likely that BE-PCV-14 will have similar effectiveness across regions. In conclusion, BE-PCV-14 was safe, well tolerated and showed comparable safety profile to that of PCV-13. BE-PCV-14 elicited immune responses non-inferior to PCV-13 in infants for all 12 common serotypes. Statistical NI was also met for two new serotypes 22F and 33F in BE-PCV-

14 vaccine. BE-PCV-14 also induced cross protective antibodies against serotype 6A. These data support BE-PCV-14 protection against 14 pneumococcal serotypes and potential benefit against serotype 6A.

Acknowledgement

We are thankful to all the study participants, the principal investigators, and the study staff at all the clinical sites. We are thankful to all the study participants, the principal investigators, and the study staff at all the clinical sites. The authors would like to thank Scientific Advisory Board (SAB) and the Management of Biological E Limited for their support and valuable guidance. All authors wish to express their appreciation and gratitude for all front-line healthcare workers. Development of this vaccine would not have been possible without the efforts of R&D team, manufacturing, quality control, quality assurance and regulatory teams at Biological E. We would also like to thank the members of the DSMB for safety monitoring of the study data. Authors would like to thank Dr. Pothakamuri Venkata Suneetha for her valuable support in drafting, reviewing and finalizing the manuscript, and Mr. Kalyan Kumar P, Mr. Raju Esanakarra & Mr. Naga Ganesh B for clinical site management and monitoring.

Conflicts of Interest:

RVM, ST, SG, VY, RM, KT and PP are employees of Biological E Limited and they do not have any stock options or incentives. All the other participating authors declare no conflicts of interest.

Data Sharing Agreement

Page 18 of 29

Study data presented in the manuscript can be made available upon request and addressed to the corresponding author Dr. Ramesh V Matur at his email: Ramesh.Matur@biologicale.com

386

387

REFERENCES

- 390 1. Publication WHO. Pneumococcal vaccines WHO position paper 2012 -
- 391 recommendations. *Vaccine* 2012; **30**(32): 4717-8.
- 2. Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. *Clin*
- 393 *Microbiol Infect* 2014; **20 Suppl 5**: 45-51.
- 394 3. Wahl B, O'Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and
- Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global,
- regional, and national estimates for 2000-15. *Lancet Glob Health* 2018; **6**(7): e744-e57.
- 397 4. Kolhapure S, Yewale V, Agrawal A, Krishnappa P, Soumahoro L. Invasive
- Pneumococcal Disease burden and PCV coverage in children under five in Southeast Asia:
- implications for India. *J Infect Dev Ctries* 2021; **15**(6): 749-60.
- 400 5. Bravo LC, Asian Strategic Alliance for Pneumococcal Disease Prevention Working G.
- 401 Overview of the disease burden of invasive pneumococcal disease in Asia. Vaccine 2009;
- **27**(52): 7282-91.
- 403 6. Geno KA, Gilbert GL, Song JY, et al. Pneumococcal Capsules and Their Types: Past,
- 404 Present, and Future. *Clin Microbiol Rev* 2015; **28**(3): 871-99.
- 405 7. ANTIBIOTIC RESISTANCE THREATS IN THE UNITED STATES. 2019.
- 406 <u>www.cdc.gov/DrugResistance/Biggest-Threats.html.</u>
- 407 8. Niederman MS, Folaranmi T, Buchwald UK, Musey L, Cripps AW, Johnson KD.
- 408 Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and
- 409 noninvasive pneumococcal disease and related outcomes: a review of available evidence. Expert
- 410 Rev Vaccines 2021; **20**(3): 243-56.
- 411 9. Clutterbuck EA, Lazarus R, Yu LM, et al. Pneumococcal conjugate and plain
- 412 polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012;
- **205**(9): 1408-16.
- 414 10. Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal
- conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis
- 416 2014; **59**(8): 1066-73.
- 417 11. McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-Valent Pneumococcal
- 418 Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US
- 419 Adults: A Test-Negative Design. *Clin Infect Dis* 2018; **67**(10): 1498-506.
- 420 12. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal
- disease in the era of conjugate vaccine. J Infect Dis 2010; **201**(1): 32-41.
- 422 13. Tomczyk S, Lynfield R, Schaffner W, et al. Prevention of Antibiotic-Nonsusceptible
- Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. Clin
- 424 Infect Dis 2016; **62**(9): 1119-25.
- 425 14. Vadlamudi NK, Chen A, Marra F. Impact of the 13-Valent Pneumococcal Conjugate
- Vaccine Among Adults: A Systematic Review and Meta-analysis. Clin Infect Dis 2019; **69**(1):
- 427 34-49.
- 428 15. Wantuch PL, Avci FY. Invasive pneumococcal disease in relation to vaccine type
- 429 serotypes. *Hum Vaccin Immunother* 2019; **15**(4): 874-5.
- 430 16. Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus
- pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and
- 432 meta-analysis. *PLoS One* 2017; **12**(5): e0177113.

- 433 17. Jaiswal N, Singh M, Das RR, et al. Distribution of serotypes, vaccine coverage, and
- antimicrobial susceptibility pattern of Streptococcus pneumoniae in children living in SAARC
- countries: a systematic review. *PLoS One* 2014; **9**(9): e108617.
- 436 18. Manoharan A, Manchanda V, Balasubramanian S, et al. Invasive pneumococcal disease
- in children aged younger than 5 years in India: a surveillance study. Lancet Infect Dis 2017;
- 438 **17**(3): 305-12.
- 439 19. Amin-Chowdhury Z, Groves N, Sheppard CL, et al. Invasive pneumococcal disease due
- to 22F and 33F in England: A tail of two serotypes. *Vaccine* 2021; **39**(14): 1997-2004.
- 441 20. Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing
- invasive pneumococcal disease in England and Wales, 2000-17: a prospective national
- observational cohort study. *Lancet Infect Dis* 2018; **18**(4): 441-51.
- 444 21. NewDrugs_CTRules_2019.

2019.

- https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-
- documents/NewDrugs_CTRules_2019.pdf.
- 447 22. Wernette CM, Frasch CE, Madore D, et al. Enzyme-linked immunosorbent assay for
- 448 quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol
- 449 2003; **10**(4): 514-9.
- 450 23. Standardization WECoB. Recommendations to assure the quality, safety and efficacy of
- 451 pneumococcal conjugate vaccines. 2013. https://cdn.who.int/media/docs/default-
- 452 <u>source/biologicals/vaccine-</u>
- standardization/pneumococcus/trs_977_annex_3.pdf?sfvrsn=344f81e_3&download=true.
- 454 24. Bratcher PE, Park IH, Hollingshead SK, Nahm MH. Production of a unique
- pneumococcal capsule serotype belonging to serogroup 6. *Microbiology (Reading)* 2009; **155**(Pt
- 456 2): 576-83.
- 457 25. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm MH. Discovery of
- a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol
- 459 2007; **45**(4): 1225-33.
- 460 26. Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent
- 461 pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing
- responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. *Vaccine* 2011; **29**(41):
- 463 7207-11.
- 464 27. Clarke E, Bashorun A, Adigweme I, et al. Immunogenicity and safety of a novel ten-
- valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3,
- randomised, double-blind, non-inferiority trial. *Lancet Infect Dis* 2021; **21**(6): 834-46.
- 467 28. Yu X, Gray B, Chang S, Ward JI, Edwards KM, Nahm MH. Immunity to cross-reactive
- serotypes induced by pneumococcal conjugate vaccines in infants. J Infect Dis 1999; **180**(5):
- 469 1569-76.
- 470 29. Kim HW, Lee S, Kim KH. Serotype 6B from a pneumococcal polysaccharide vaccine
- 471 induces cross-functional antibody responses in adults to serotypes 6A, 6C, and 6D. *Medicine*
- 472 (Baltimore) 2016; **95**(37): e4854.
- 473 30. Ricketson LJ, Bettinger JA, Sadarangani M, Halperin SA, Kellner JD, Canadian
- 474 Immunization Monitoring Program AI. Vaccine effectiveness of the 7-valent and 13-valent
- pneumococcal conjugate vaccines in Canada: An IMPACT study. Vaccine 2022; 40(19): 2733-
- 476 40.

Page 21 of 29

- 477 31. Owusu-Edusei K, Deb A, Johnson KD. Estimates of the Health and Economic Burden of
- Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine
- 479 Serotypes in the USA. *Infect Dis Ther* 2022; **11**(3): 987-99.
- 480 32. Demczuk WH, Martin I, Griffith A, et al. Serotype distribution of invasive Streptococcus
- pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine,
- 482 2010-2012. Can J Microbiol 2013; **59**(12): 778-88.

- 483 33. Banniettis N, Wysocki J, Szenborn L, et al. A phase III, multicenter, randomized, double-
- blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity
- of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in
 - healthy infants, children, and adolescents (PNEU-PLAN). Vaccine 2022; 40(44): 6315-25.

Page 22 of 29

Tables:

523524525

526

527

TABLE 1: Demographic characteristics of study participants

Parameter/	BE-PCV-14	PCV-13	Overall	
Statistics/Category	(N=645)	(N=645)	(N=1290)	
Age (Days)		,		
N1	645	645	1290	
Mean	48.3	48.3	48.3	
SD	3.75	3.69	3.72	
Median	48.0	48.0	48.0	
Range (Min: Max)	(42.0:56.0)	(42.0:56.0)	(42.0:56.0)	
Gender, N1 (%)				
Male	342 (53.0%)	365 (56.6%)	707(54.8%)	
Female	303 (47.0%)	280 (43.4%)	583(45.2%)	
Height (Cms)				
N1	645	645	1290	
Mean	52.0	52.0	52.0	
SD	3.76	4.03	3.89	
Median	51.4	51.2	51.3	
Range (Min: Max)	(40.0:69.0)	(41.0:72.0)	(40.0:72.0)	
Weight (Gms)				
N1	645	645	1290	
Mean	4162.9	4165.7	4164.3	
SD	526.85	526.44	526.44	
Median	4100.0	4100.0	4100.0	
Range (Min: Max)	(3300.0:6000.0)	(3300.0:6300.0)	(3300.0:6300.0)	
Nationality, N1 (%)				
Indian	645 (100.0%)	645 (100.0%)	1290(100.0%)	
ВМІ				
N1	645	645	1290	
Mean	15.5	15.5	15.5	
SD	2.19	2.31	2.25	
Median	15.6	15.7	15.7	
Range (Min: Max)	(8.0:25.0)	(8.0:26.5)	(8.0:26.5)	

 $\textbf{Note:} \ \ \mathsf{Percentages} \ \ \mathsf{were} \ \mathsf{calculated} \ \ \mathsf{using} \ \ \mathsf{respective} \ \ \mathsf{column} \ \ \mathsf{header} \ \ \mathsf{count} \ \ \mathsf{as} \ \ \mathsf{denominator}.$

N₁: Subject Count, N: Sample Size.

Table 2: Summary of serotype-specific OPA titer \geq LLOQ (\geq 1:8) in terms of seroconversion rates, GMTs and fold rise.

Serotype	OPA sero-co		OPA (GMTs	subjects least 4 fo OPA GN	ld rise in	GN	1FR
	BE-PCV-14	PCV-13	BE-PCV- 14	PCV-13	BE-PCV- 14	PCV-13	BE-PCV- 14	PCV-13
Serotype 1	63.64	64.43	23.21	19.94	45.99	42.78	3.81	3.32
Serotype 3	71.81	79.58	59.6	63.01	62.77	61.26	9.97	9.86
Serotype 4	93.68	91.75	426.67	626.04	73.16	73.71	25.92	52.55
Serotype 5	80.73	84.1	66.47	78.17	60.94	66.67	8.95	11.61
Serotype 6B	88.48	88.21	990.66	918.24	70.68	68.72	26.32	27.9
Serotype 7F	97.4	98.46	1023.16	1156.95	71.35	76.92	14.56	19.97
Serotype 9V	97.92	97.94	856.81	746.44	78.65	72.16	24.18	27.22
Serotype 14	95.81	97.44	1951.14	1272.2	61.78	61.03	16.85	13.37
Serotype 18C	93.23	94.36	460.7	561.01	63.02	64.1	15.89	23.39
Serotype 19A	95.83	95.9	394.65	451.18	68.75	76.41	17.57	22.2
Serotype 19F	94.79	92.31	604.3	439.94	83.33	79.49	34.88	26.39
Serotype 23F	97.37	98.46	768.79	995.13	68.42	73.85	16.77	27.8
Serotype 22F	98.43	NA	691.6	NA	61.26	NA	15.16	NA
Serotype 33F	94.18	NA	1859.67	NA	60.85	NA	16.91	NA

Table 3: Proportion of subjects achieving ≥4-fold increase in anti-PnCPS IgG antibody concentrations

536

Auti DucDC laC against as shipf	BE-PCV14	PCV-13
Anti-PnCPS IgG against each of the vaccine serotype post	(N=641)	(N=626)
vaccination (Day 86)	N1 (%) [95% CI]	(N-020) N1 (%) [95% CI]
vaccination (Day 80)	N1 (%) [93% CI]	
Sorotuno 1	394 (61.5%)	441 (70.4%) [66.70:74.00]
Serotype 1	[57.58:65.25]	[00.70.74.00]
	299 (46.6%)	253 (40.4%)
Serotype 3	[42.73:50.59]	[36.54:44.38]
	[42.73.30.39]	
	241 (37.6%)	294 (47.0%)
Serotype 4	[33.83:41.48]	[43.00:50.96]
	[33.63.41.46]	
	388 (60.5%)	358 (57.2%)
Serotype 5	[56.63:64.34]	[53.21:61.10]
	[30.03.04.34]	
	341 (53.2%)	324 (51.8%)
Serotype 6B	341 (33.2%) [49.25:57.12]	[47.76:55.74]
	[49.23.37.12]	
	455 (71.0%)	463 (74.0%)
Serotype 7F	[67.30:74.47]	[70.34:77.36]
	[07.30.74.47]	
	422 (65.8%)	390 (62.3%)
Serotype 9V	[62.02:69.50]	[58.37:66.11]
	[02.02.03.30]	
	172 (26.8%)	157 (25.1%)
Serotype 14	[23.44:30.44]	[21.73:28.67]
	[23.44.30.44]	
	230 (35.9%)	243 (38.8%)
Serotype 18C	[32.16:39.73]	[34.98:42.76]
	[32.10.33.73]	
	212 (33.1%) [29.44:36.87]	230 (36.7%)
Serotype 19A		[32.95:40.65]
	[23,44,30,67]	
	410 (64.0%)	419 (66.9%)
Serotype 19F	[60.11:67.69]	[63.09:70.61]
	[60.11.07.03]	

Page 25 of 29

Anti-PnCPS IgG against each of	BE-PCV14	PCV-13
the vaccine serotype post	(N=641)	(N=626)
vaccination (Day 86)	N1 (%) [95% CI]	N1 (%) [95% CI]
Saveture 22F	362 (56.5%)	371 (59.3%)
Serotype 23F	[52.54:60.35]	[55.30:63.14]

Note: Percentage was calculated using respective header count as denominator 95% CI for was calculated using Clopper Pearson Method .

Page 26 of 29

Table 4: Serotype-6A specific IgG and OPA immune responses:

ST-6A IgG GMC (N=1290)	Pre-Vac	Post-Vac	GMFR	ST-6A OPA GMT (N=386)	Pre-Vac	Post-Vac	GMFR
BE-PCV- 14 (n=645)	0.448	1.075	2.4	BE- PCV14 (n=192)	16.59	134.50	7.64
PCV-13 (n=645)	0.446	1.906	4.27	PCV-13 (n=194)	19.20	690.63	37.35

Table 5: Overview of AEs- solicited and unsolicited AEs

Category	BE-PCV-14	PCV-13
N1 (%) [95% CI] n	(N=645)	(N=645)
Overall AEs	175 (27.1%)	178 (27.6%)
Overall AES	[23.73:30.74] 355	[24.18:31.22] 353
Serious AEs	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0
Severe AEs	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0
Lacal AFa	137 (21.2%)	144 (22.3%)
Local AEs	[18.14:24.60] 235	[19.17:25.74] 251
Customia A.F.s	70 (10.9%)	63 (9.8%)
Systemic AEs	[8.56:13.51] 118	[7.59:12.32] 101
Medically Attended AEs	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0
A.E. within 60 minutes nectives	4 (0.6%)	4 (0.6%)
AEs within 60 minutes postvac	[0.17:1.58] 6	[0.17:1.58] 5
A.E. within 7 days posture	174 (27.0%)	178 (27.6%)
AEs within 7 days postvac	[23.59:30.58] 354	[24.18:31.22] 352
AEs between Day 0 to Day 28	115 (17.8%)	109 (16.9%)
AES DELWEET Day 0 to Day 26	[14.95:21.01] 207	[14.09:20.02] 190
AFs hotwood Doy 29 to Doy F6	61 (9.5%)	73 (11.3%)
AEs between Day 28 to Day 56	[7.31:11.98] 93	[8.98:14.02] 110
AEs between Day 56 to Day 86	46 (7.1%)	41 (6.4%)
AES DELWEET Day 50 to Day 60	[5.27:9.40] 55	[4.60:8.52] 53
Any Solicited AEs	174 (27.0%)	178 (27.6%)
Any Solicited AEs	[23.59:30.58] 353	[24.18:31.22] 352
Any Unsolicited AEs	2 (0.3%)	1(0.2%)[0.00:0.86]1
Any onsolicited Aes	[0.04:1.12] 2	1(0.2%)[0.00.0.86]1

Note: Percentages were calculated using respective column header group count as denominator. 95% CI was calculated by Clopper-Pearson Method.

N1: Subject Count, N: Subject Count, N: Sample Size, n: Event Count

General Note:

- All AE's were represented as: Subject count (Percentage of subjects) [95% CI] Event Count.
- Solicited Local and Systemic AEs were recored during 7 days (Day 0 Day 6) after the vaccination.
- Unsolicited adverse event reported at any time, until 28 days after the vaccination.

570

571

568

Table 6: Summary of AEs by SOC and PT

573

574

SOC/PT,	BE-PCV-14	PCV-13
N1 (%) [95% CI] n	(N=645)	(N=645)
Overall	175 (27.1%) [23.73:30.74] 355	178 (27.6%) [24.18:31.22] 353
Gastrointestinal disorders	9 (1.4%) [0.64:2.63] 12	5 (0.8%) [0.25:1.80] 8
Abdominal pain	1 (0.2%) [0.00:0.86] 1	0 (0.0%) [NE] 0
Diarrhoea	6 (0.9%) [0.34:2.01] 8	2 (0.3%) [0.04:1.12] 3
Vomiting	3 (0.5%) [0.10:1.35] 3	4 (0.6%) [0.17:1.58] 5
General disorders and administration site conditions	169 (26.2%) [22.85:29.78] 329	173 (26.8%) [23.44:30.42] 333
Injection site erythema	33 (5.1%) [3.55:7.11] 38	36 (5.6%) [3.94:7.64] 44
Injection site induration	9 (1.4%) [0.64:2.63] 13	13 (2.0%) [1.08:3.42] 18
Injection site pain	93 (14.4%) [11.80:17.37] 133	98 (15.2%) [12.51:18.20] 131
Injection site swelling	44 (6.8%) [5.00:9.05] 51	48 (7.4%) [5.54:9.75] 58
Irritability Postvaccinal	25 (3.9%) [2.52:5.67] 41	21 (3.3%) [2.03:4.93] 31
Pyrexia	42 (6.5%) [4.73:8.70] 53	40 (6.2%) [4.47:8.35] 51
Metabolism and nutrition disorders	8 (1.2%) [0.54:2.43] 9	6 (0.9%) [0.34:2.01] 10
Decreased appetite	8 (1.2%) [0.54:2.43] 9	6 (0.9%) [0.34:2.01] 10
Nervous system disorders	2 (0.3%) [0.04:1.12] 4	1 (0.2%) [0.00:0.86] 2
Somnolence	2 (0.3%) [0.04:1.12] 4	1 (0.2%) [0.00:0.86] 2
Respiratory, thoracic and mediastinal disorders	1 (0.2%) [0.00:0.86] 1	0 (0.0%) [NE] 0
Cough	1 (0.2%) [0.00:0.86] 1	0 (0.0%) [NE] 0

Note: Percentages were calculated using column header group count as denominator.

95% CI were calculated by Clopper -Pearson Method.

N1: Subject Count, N: Sample Size, n: Event Count

General Note:

575

576

577

578

579


• All AE's were represented as: Subject count (Percentage of subjects) [95% CI] Event Count.

Table 7: Overview AEs by Severity & Causality

Category N1 (%) [95% CI] n	BE-PCV-14 (N=645)	PCV-13 (N=645)	
Number of subjects with at least	175 (27.1%)	178 (27.6%)	
one AE	[23.73:30.74] 355	[24.18:31.22] 353	
Number of subjects with at least one SAE	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0	
Number of subjects with at least one MAAE	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0	
Severity			
Mild	174 (27.0%)	177 (27.4%)	
ivilia	[23.59:30.58] 343	[24.03:31.06] 338	
Madarata	6 (0.9%)	10 (1.6%)	
Moderate	[0.34:2.01] 12	[0.75:2.83] 15	
Severe	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0	
Life-threatening	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0	
Causality			
Contain	61 (9.5%)	65 (10.1%)	
Certain	[7.31:11.98] 79	[7.86:12.66] 79	
Due le elele	73 (11.3%)	68 (10.5%)	
Probable	[8.98:14.02] 84	[8.28:13.17] 77	
Describle	48 (7.4%)	53 (8.2%)	
Possible	[5.54:9.75] 185	[6.22:10.61] 194	
11,-19,-1.	5 (0.8%)	3 (0.5%)	
Unlikely	[0.25:1.80] 6	[0.10:1.35] 3	
 Unrelated	1 (0.2%) [0.00:0.86] 1	0 (0.0%) [NE] 0	
Unclassifiable	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0	
Related (Certain/Probable/	173 (26.8%)	177 (27.4%)	
Possible)	[23.44:30.42] 348	[24.03:31.06] 350	
Unrelated	5 (0.8%)	3 (0.5%)	
(Unlikely/Unrelated/Unclassifiable)	[0.25:1.80] 7	[0.10:1.35] 3	
Number of subjects discontinued due to AE	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0	

580

Figure 2a: Difference in proportion of seroconversion rates with 95% confidence intervals




	Percent seroresponse rate	Percent seroresponse rate	Proportion of difference
Serotypes	of BE-PCV-14 serotypes#	of PCV-13 serotypes#	between groups (95% CI)
Serotype 1	90.60%	93.30%	-2.7 [-5.65 : 0.35]
Serotype 3	83.50%	77.00%	6.5 [2.08 : 10.85]
Serotype 4	93.10%	95.20%	-2.1 [-4.65 : 0.51]
Serotype 5	90.60%	89.90%	0.7 [-2.56 : 3.96]
Serotype 6B	76.30%	79.40%	-3.1 [-7.68 : 1.47]
Serotype 7F	95.80%	95.70%	0.1 [-2.12 : 2.33]
Serotype 9V	95.20%	93.30%	1.9 [-0.69 : 4.44]
Serotype 14	99.70%	100.00%	-0.3 [-0.75 : 0.13]
Serotype 18C	90.50%	93.30%	-2.8 [-5.82 : 0.20]
Serotype 19A	99.40%	99.50%	-0.1 [-0.96 : 0.67]
Serotype 19F	97.20%	97.90%	-0.7 [-2.43 : 0.97]
Serotype 23F	82.40%	85.10%	-2.8 [-6.84 : 1.29]
Serotype 22F*	94.10%	77% (serotype 3)	17.1 [13.21 : 20.94]
Serotype 33F*	73.20%	77% (serotype 3)	-3.8 [-8.60 : 0.94]

#Total number of study subjects included for analysing serotype specific seroresponsiveness in BE-PCV-14 group: n=641

#Total number of study subjects included for analysing serotype specific seroresponsiveness in BE-PCV-14 group: n=626

*For serotypes 22F and 33F (which are not present in PCV-13) seroresponse rates and GMC for the BE-PCV-14 group were compared with those for the serotype in the PCV-13 group with the lowest seroresponse rate (i.e. serotype 3).

Figure 2b: Geometric Mean Concentration ratios with 95% confidence intervals



Serotypes	BE-PCV-14: GMC	PCV-13: GMC	GMC ratio (95% CI)
Serotype 1	1.73	2.26	0.77 (0.67:0.88)
Serotype 3	0.85	0.7	1.23 (1.10:1.37)
Serotype 4	1.75	2.1	0.83 (0.74:0.94)
Serotype 5	1.48	1.4	1.06 (0.93:1.20)
Serotype 6B	1.69	1.8	0.94 (0.76:1.15
Serotype 7F	2.89	3.3	0.88 (0.76:1.01)
Serotype 9V	3.03	2.72	1.12 (0.95:1.31)
Serotype 14	11.18	9.52	1.18 (1.01:1.37)
Serotype 18C	2.36	2.65	0.89 (0.76:1.04)
Serotype 19A	5.39	6.02	0.89 (0.77:1.04)
Serotype 19F	5.63	6.51	0.87 (0.74:1.01)
Serotype 23F	2.03	2.19	0.92 (0.77:1.11)
Serotype 22F*	4.18	0.7 (serotype 3)	6.01 (5.26:6.87)
Serotype 33F*	1.5	0.7 (serotype 3)	2.16 (1.82:2.56)

^{*}For serotypes 22F and 33F (which are not included in PCV-13), GMC of the BE-PCV-14 group were compared with those for the serotype in the PCV-13 group with the lowest GMC (i.e. serotype 3).

Figure 3: Reverse cumulative distribution (RCD) curves of anti-PnCPS IgG antibody concentrations for 12 common serotypes between BE-PCV-14 and PCV-13.

